Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.
Nivolumab/纳武单抗 细胞实验
Cell Line
Concentration
Treated Time
Description
References
Dendritic cells (DCs)
20 µg/ml
24 hours
To evaluate the effect of nivolumab on IFN-γ-producing effector T cells induced by DCs loaded with sunitinib-treated sarcoma cells. Results showed that nivolumab significantly increased the number of IFN-γ-producing CD8+ T cells.
Front Immunol. 2021 Feb 26;12:577766
MSI-H IM95 gastric cancer cell line-derived organoids
0.5 μg/ml
48 hours
To study the effect of nivolumab on MSI-H IM95 gastric cancer cell line-derived organoids, results showed increased CTL proliferation and organoid death in the absence of MDSCs.
Cancer Lett. 2021 Oct 10;518:59-71
PD-L1-expressing organoids
0.5 μg/ml
48 hours
To study the effect of nivolumab on PD-L1-expressing organoids in vitro, results showed that organoids were unresponsive to nivolumab in the presence of PMN-MDSCs.
Cancer Lett. 2021 Oct 10;518:59-71
T cells
90 μg/ml
48 hours
To evaluate the effect of different concentrations of Nivolumab on T cell activation, results showed that 90 μg/ml increased the percentage of CD25 and CD69 positive cells.
Sci Rep. 2022 May 19;12(1):8370
T cells
60 μg/ml
48 hours
To evaluate the effect of different concentrations of Nivolumab on T cell activation, results showed that 60 μg/ml increased the percentage of CD25 and CD69 positive cells.
Sci Rep. 2022 May 19;12(1):8370
T cells
30 μg/ml
48 hours
To evaluate the effect of different concentrations of Nivolumab on T cell activation, results showed that 30 μg/ml increased the percentage of CD25 and CD69 positive cells.
Sci Rep. 2022 May 19;12(1):8370
T cells
10 μg/ml
48 hours
To evaluate the effect of different concentrations of Nivolumab on T cell activation, results showed that 10 μg/ml significantly increased the percentage of CD25 and CD69 positive cells.
Sci Rep. 2022 May 19;12(1):8370
Human monocyte-derived dendritic cells (hMDDC)
0.625 µg/mL
5 days
Blocking the PD-1/PD-L interaction significantly increased T-cell proliferation and release of proinflammatory cytokines TNFα and IFNγ, thereby significantly reducing Lm infection.
Front Immunol. 2017 Dec 22;8:1880
Human monocyte-derived macrophages type 2 (hMDM2)
0.625 µg/mL
5 days
Blocking the PD-1/PD-L interaction increased T-cell proliferation but had no significant effect on Lm infection rate.
Front Immunol. 2017 Dec 22;8:1880
Human monocyte-derived macrophages type 1 (hMDM1)
0.625 µg/mL
5 days
Blocking the PD-1/PD-L interaction increased T-cell proliferation and release of proinflammatory cytokines TNFα and IFNγ, thereby reducing Lm infection.
Front Immunol. 2017 Dec 22;8:1880
T cells
20 µg/ml
5 days
To evaluate the effect of nivolumab on T cell proliferation and subpopulation composition after DCs were loaded with sunitinib-treated sarcoma cells. Results showed that nivolumab increased PD-1 expression on CD4+ and CD8+ T cells.
Front Immunol. 2021 Feb 26;12:577766
U87
20 µg/mL
5 hours
Evaluate the long-term cytotoxicity of GD2 CAR-T in combination with Nivolumab. Results showed a cytotoxic efficiency of 40.47 ±8.3% and residual elimination ability of 43.44 ±7.83% at the fifth-round re-challenge.
Transl Oncol. 2023 Jun;32:101663
U251
20 µg/mL
5 hours
Evaluate the long-term cytotoxicity of GD2 CAR-T in combination with Nivolumab. Results showed a cytotoxic efficiency of 23.4 ±2.18% and maintained a residual elimination ability of 26.63 ±2.35% at the fifth round of re-challenging.
Transl Oncol. 2023 Jun;32:101663
Human PBMCs
10 µg/ml
6 days
To assess the effect of PD-1 blockade on IFN-γ secretion in PBMCs, it was found that PD-1 blockade increased IFN-γ secretion, but no correlation with clinical response was observed.
Cancer Immunol Immunother. 2024 Jul 5;73(9):181
Human T cells
10 µg/ml
6 days
To study the effect of PD-1 blockade on T cell IFN-γ secretion, it was found that PD-1 blockade increased IFN-γ secretion, while IFN-α reduced IFN-γ secretion in the presence of PD-1 blockade.
Cancer Immunol Immunother. 2024 Jul 5;73(9):181
Peripheral CD8+ T-lymphocytes
10 μg/ml
7 days
PD-1 expression was decreased in a concentration-dependent manner
BMC Cancer. 2019 Nov 6;19(1):1053
LoVo
100 nM, 1 µM, 10 µM
72 hours
To evaluate the effect of Nivolumab on cell growth. Results showed that Nivolumab increased LoVo cell growth (1.4-fold).
J Immunother Cancer. 2022 Mar;10(3):e004032
HCT116
100 nM, 1 µM, 10 µM
72 hours
To evaluate the effect of Nivolumab on cell growth. Results showed that Nivolumab increased HCT116 cell growth (2.5-fold).
J Immunother Cancer. 2022 Mar;10(3):e004032
HT29
100 nM, 1 µM, 10 µM
72 hours
To evaluate the effect of Nivolumab on cell growth. Results showed that Nivolumab increased HT29 cell growth (1.6-fold).
J Immunother Cancer. 2022 Mar;10(3):e004032
HCC827GR cells
20 μg/mL
72 hours
To evaluate the inhibitory effect of nivolumab combined with anti-TGF-β antibody on the proliferation of EGFR-TKI resistant tumor cells. Results showed that the combination treatment significantly inhibited the proliferation of HCC827GR cells.
J Transl Med. 2024 Jul 14;22(1):653
PC9OR cells
20 μg/mL
72 hours
To evaluate the inhibitory effect of nivolumab combined with anti-TGF-β antibody on the proliferation of EGFR-TKI resistant tumor cells. Results showed that the combination treatment significantly inhibited the proliferation of PC9OR cells.
J Transl Med. 2024 Jul 14;22(1):653
L-428 cells
10 μg/mL
Overnight
To evaluate the effect of Nivolumab on the duration of T cell-HRS cell contacts, results showed Nivolumab had no significant effect on the contact duration with L-428 cells
Haematologica. 2024 Oct 1;109(10):3295-3304
L-1236 cells
10 μg/mL
Overnight
To evaluate the effect of Nivolumab on the duration of T cell-HRS cell contacts, results showed Nivolumab significantly increased the contact duration between resting CD4+ T cells and L-1236 cells
Haematologica. 2024 Oct 1;109(10):3295-3304
Nivolumab/纳武单抗 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/C nude mice
Subcutaneous pancreatic cancer model
Intravenous injection
0.1 μg/ml nivolumab + IFN-γ
5 times at 4-day intervals
Significant inhibition of tumor growth
BMC Cancer. 2019 Nov 6;19(1):1053
NOD/SCID mice
Orthotopic glioblastoma models
Intraperitoneal injection
10 mg/kg
Weekly, continuous observation
Evaluate the anti-tumor efficacy of GD2 CAR-T in combination with Nivolumab. Results showed a significant reduction in tumor burden and extended median survival time to ~50 days.
Transl Oncol. 2023 Jun;32:101663
Humanized M-NSG mice
EGFR-TKI resistant tumor model
Intraperitoneal injection
200 μg
Every 3 to 4 days until the end of the experiment
To evaluate the inhibitory effect of nivolumab combined with anti-TGF-β antibody on EGFR-TKI resistant tumors. Results showed that the combination treatment significantly inhibited tumor growth and prolonged the survival of mice.
J Transl Med. 2024 Jul 14;22(1):653
NSG mice
NPC-PDX model
Intravenous injection
5 mg/kg
Once a week for four weeks
Evaluate the antitumor effect of CAR NK92 cells in the NPC-PDX model. Results showed that CAR NK92 cells significantly inhibited tumor growth.
Sci Adv. 2022 Nov 25;8(47):eadd1187
Female Athymic Nude mice
HT29 colon cancer xenograft model
Intraperitoneal
5 mg/kg
Twice a week for 3 weeks
To evaluate the effect of Nivolumab on tumor growth. Results showed that Nivolumab significantly increased HT29 tumor growth (1.88-fold).
搜索
